Skip to main content

Table 1 The tumor growth inhibitions (TGIs) and Ki-67 scores after gimatecan treatment in five xenografts

From: Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways

No. of PDX model

TGIs (%)

Ki-67 (%)

Gimatecan

Irinotecan

Control

Gimatecan

Irinotecan

1

110.1

75.4

–a

–a

–a

2

106.6

76.1

100

60

60

3

84.4

24.1

70

10

70

4

91.7

15.1

70

40

60

5

108.7

40.6

40

10

50

  1. aNo tissue was available for immunohistochemistry assay after the treatment